These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33589921)

  • 1. Prolactin Drives a Dynamic STAT5A/HDAC6/HMGN2 Cis-Regulatory Landscape Exploitable in ER+ Breast Cancer.
    Craig JM; Turner TH; Harrell JC; Clevenger CV
    Endocrinology; 2021 May; 162(5):. PubMed ID: 33589921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth.
    Medler TR; Craig JM; Fiorillo AA; Feeney YB; Harrell JC; Clevenger CV
    Mol Cancer Res; 2016 Oct; 14(10):994-1008. PubMed ID: 27358110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription.
    Fiorillo AA; Medler TR; Feeney YB; Liu Y; Tommerdahl KL; Clevenger CV
    Mol Endocrinol; 2011 Sep; 25(9):1550-64. PubMed ID: 21816901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism.
    Tran TH; Utama FE; Lin J; Yang N; Sjolund AB; Ryder A; Johnson KJ; Neilson LM; Liu C; Brill KL; Rosenberg AL; Witkiewicz AK; Rui H
    Cancer Res; 2010 Feb; 70(4):1711-21. PubMed ID: 20124477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells.
    Fang F; Rycyzyn MA; Clevenger CV
    Endocrinology; 2009 Apr; 150(4):1597-606. PubMed ID: 19036881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone H1 and Chromosomal Protein HMGN2 Regulate Prolactin-induced STAT5 Transcription Factor Recruitment and Function in Breast Cancer Cells.
    Schauwecker SM; Kim JJ; Licht JD; Clevenger CV
    J Biol Chem; 2017 Feb; 292(6):2237-2254. PubMed ID: 28035005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transcriptional responsiveness of LKB1 to STAT-mediated signaling is differentially modulated by prolactin in human breast cancer cells.
    Linher-Melville K; Singh G
    BMC Cancer; 2014 Jun; 14():415. PubMed ID: 24913037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HDAC6-mediated progesterone receptor expression on the response of breast cancer cells to hormonal therapy.
    Ramadan WS; Alseksek RK; Mouffak S; Talaat IM; Saber-Ayad MM; Menon V; Ilce BY; El-Awady R
    Eur J Pharmacol; 2024 Nov; 983():177001. PubMed ID: 39284403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serine residues 726 and 780 have nonredundant roles regulating STAT5a activity in luminal breast cancer.
    Woock AE; Grible JM; Olex AL; Harrell JC; Zot P; Idowu M; Clevenger CV
    Sci Rep; 2021 Jun; 11(1):13506. PubMed ID: 34188118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT5A is regulated by DNA damage via the tumor suppressor p53.
    Mukhopadhyay UK; Cass J; Raptis L; Craig AW; Bourdeau V; Varma S; SenGupta S; Elliott BE; Ferbeyre G
    Cytokine; 2016 Jun; 82():70-9. PubMed ID: 26876578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking.
    Subtil-Rodríguez A; Millán-Ariño L; Quiles I; Ballaré C; Beato M; Jordan A
    Mol Cell Biol; 2008 Jun; 28(11):3830-49. PubMed ID: 18378698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis.
    Yang X; Meyer K; Friedl A
    J Biol Chem; 2013 Jul; 288(29):21184-21196. PubMed ID: 23729680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling.
    Tran TH; Utama FE; Sato T; Peck AR; Langenheim JF; Udhane SS; Sun Y; Liu C; Girondo MA; Kovatich AJ; Hooke JA; Shriver CD; Hu H; Palazzo JP; Bibbo M; Auer PW; Flister MJ; Hyslop T; Mitchell EP; Chervoneva I; Rui H
    Clin Cancer Res; 2018 Dec; 24(24):6355-6366. PubMed ID: 30097435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
    Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD
    Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT5 Regulation of Sex-Dependent Hepatic CpG Methylation at Distal Regulatory Elements Mapping to Sex-Biased Genes.
    Hao P; Waxman DJ
    Mol Cell Biol; 2021 Jan; 41(2):. PubMed ID: 33199496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
    Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
    Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen stimulates transcription from the human prolactin distal promoter through AP1 and estrogen responsive elements in T47D human breast cancer cells.
    Duan R; Ginsburg E; Vonderhaar BK
    Mol Cell Endocrinol; 2008 Jan; 281(1-2):9-18. PubMed ID: 18022314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B.
    Verdier F; Rabionet R; Gouilleux F; Beisenherz-Huss C; Varlet P; Muller O; Mayeux P; Lacombe C; Gisselbrecht S; Chretien S
    Mol Cell Biol; 1998 Oct; 18(10):5852-60. PubMed ID: 9742102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer.
    Achinger-Kawecka J; Valdes-Mora F; Luu PL; Giles KA; Caldon CE; Qu W; Nair S; Soto S; Locke WJ; Yeo-Teh NS; Gould CM; Du Q; Smith GC; Ramos IR; Fernandez KF; Hoon DS; Gee JMW; Stirzaker C; Clark SJ
    Nat Commun; 2020 Jan; 11(1):320. PubMed ID: 31949157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor.
    Carsol JL; Gingras S; Simard J
    Mol Endocrinol; 2002 Jul; 16(7):1696-710. PubMed ID: 12089361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.